Evolution of Approaches to Viral Safety Issues for Biological Products

References

1. 1.↵
   1. Enders J. F.,
   2. Weller T. H.,
   3. Robbins F. C.

   Cultivation of the Lansing strain of poliomyelitis virus in culture. Science 1949, 109, 85–87.

   OpenUrlFREE Full Text
2. 2.↵
   1. Kalter S. S.,
   2. Ablashi D.,
   3. Espana C.,
   4. Heberling R. L.,
   5. Hull R. N.,
   6. Lennette E. H.,
   7. Malherbe H. H.,
   8. McConnell S.,
   9. Yohn D. S.

   Simian virus nomenclature, 1980. Intervirology 1980, 13 (6), 317–330.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Shah K.,
   2. Nathanson N.

   Human exposure to SV40; Review and comment. Am. J. Epidemiol. 1976, 103, 1–12.

   OpenUrlFREE Full Text
4. 4.↵
   1. Waters T. D.,
   2. Anderson P. S.,
   3. Beebe G. W.,
   4. Miller R. W.

   Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972, 177, 76–77.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Petricciani J. C.,
   2. Chu F. C.,
   3. Johnson J. B.

   Bacteriophages in live virus vaccines. Proc. Soc. Exp. Biol. Med. 1973, 144, 789–791.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Huff J. L.,
   2. Barry P. A.

   B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease. Emerg. Infect. Dis. 2003, 9 (2), 246–250.

   OpenUrlPubMedWeb of Science
7. 7.↵
   1. Martini G. A.

   Marburg agent disease: in man. Royal Soc. Trop. Med. Hyg. 1969, 63 (3), 295–301.

   OpenUrl
8. 8.↵
   1. Nathanson N.,
   2. Langmuir A. D.

   The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am. J. Hyg. 1963, 78, 29–60.

   OpenUrlPubMedWeb of Science
9. 9.↵
   1. Para M.

   An outbreak of post-vaccinal rabies (rage de laboratoire) in Fortazela, Brazil in 1960. Bull. World Health. Org. 1965, 33 (2), 177–182.

   OpenUrlPubMed
10. 10.↵
    1. Cann A. J.,
    2. Stanway G.,
    3. Hughes P. J.,
    4. Minor P. D.,
    5. Evans D. M. A.,
    6. Schild G. C.,
    7. Almond J. W.

    Reversion to neurovirulence of the live-attenuated sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984, 12 (20), 7787–7792.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Brown E. G.,
    2. Furesz J.,
    3. Dimock K.,
    4. Yarosh W.,
    5. Contreras G.

    Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. Vaccine 1991, 9 (11), 840–842.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Edelman R.,
    2. Ascher M. S.,
    3. Oster C. N.,
    4. Ramsburg H. H.,
    5. Cole F. E.,
    6. Eddy G. A.

    Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J. Infect. Dis. 1979, 140 (5), 708–715.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Bancroft W. H.,
    2. Scott R. M.,
    3. Eckels K. H.,
    4. Hoke C. H.,
    5. Simms T. E.,
    6. Jesrani K. D. T.,
    7. Summers P. L.,
    8. Dubois D. R.,
    9. Tsoulos D.,
    10. Russell P. K.

    Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J. Infect. Dis. 1984, 149 (6), 1005–1010.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Steinhauer D. A.,
    2. Domingo E.,
    3. Holland J. J.

    Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 1992, 122 (2), 281–288.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Hacein-Bey-Abina S.,
    2. von Kalle C.,
    3. Schmidt M.,
    4. Le Deist F.,
    5. Wulffraat N.,
    6. Mclntyre l.,
    7. Radford E.,
    8. Villeval J. L.,
    9. Fraser C. C.,
    10. Cavazzana-Calvo M.,
    11. Fischer A.

    A serious adverse event after successful gene therapy for X-linked severe combinedimmunodeficiency. N. Engl. J. Med. 2003, 348, 255–256.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Wilson G.

    The Hazards of Immunization; Anthlone Press, University of London: London, 1967.
17. 17.↵
    1. Sawyer W. A.,
    2. Meyer K. F.,
    3. Eaton M. D.,
    4. Bauer J. H.,
    5. Putnam P.,
    6. Schwentker F. F.

    Jaundice in Army personnel in the western region of the United States and its relation to vaccination against yellow fever. Amer. J. Hyg. 1944, 39, 337–430.

    OpenUrl
18. 18.↵
    1. Morgenthaler J. J.,
    2. Omar A.

    Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation. Dev. Biol. Stand. 1993, 81, 185–190.

    OpenUrlPubMed
19. 19.↵
    1. Dodd R. Y.

    Hepatitis C, other types of non-B parenteral hepatitis and blood transfusion. Dev. Biol. Stand. 1993, 81, 35–40.

    OpenUrlPubMed
20. 20.↵
    1. Yu M. W.

    Follow-up studies of hepatitis C association with an intravenous immunoglobulin. Dev. Biol. Stand. 1996, 81, 215–216.

    OpenUrl
21. 21.↵
    1. Barrowcliffe T. W.

    Viral inactivation vs biological activity. Dev. Biol. Stand. 1993, 81, 125–135.

    OpenUrlPubMed
22. 22.↵
    1. Garson J. A.,
    2. Tedder R. S.,
    3. Briggs M.,
    4. Tuke P.,
    5. Glazebrook J. A.,
    6. Trute A.,
    7. Parker D.,
    8. Barbara J. A.,
    9. Contreras M.,
    10. Aloysius S.

    Detection of hepatitis C viral sequences in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet 1990, 335 (8703), 1419–1422.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Saldanha J.,
    2. Minor P. D.

    Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficacy and consistency of removal of B19 DNA during manufacture. Brit. J. Haematol. 1996, 93, 714–719.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Fox J. L.

    French court rules on HIV-contaminated blood lawsuit. Am. Soc. Microbiol. News 1999, 65, 397.

    OpenUrl
25. 25.↵
    1. Nathan R.

    Guilty pleas intensify row over contaminated blood. Nature Medicine 1997, 3, 480–481.

    OpenUrlPubMed
26. 26.↵
    1. Nash D.,
    2. Mostashi F.,
    3. Fine A.

    The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 2001, 344, 1807–1814.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Owen J.,
    2. Moore F.,
    3. Panella N.

    Migrating birds as dispersal vehicles for West Nile virus. EcoHealth 2006, 3, 1–7.

    OpenUrl
28. 28.↵
    1. Pealer L. N.,
    2. Marfin A. A.,
    3. Petersen L. R.

    Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 2003, 349, 1236–1245.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Lubiniecki A. S.,
    2. May L. H.

    Cell bank characterization for recombinant DNA mammalian cell lines. Dev. Biol. Stand. 1985, 60, 141–146.

    OpenUrlPubMedWeb of Science
30. 30.↵
    1. Petricciani J. C.

    Regulatory considerations for products derived from the new biotechnology. Pharm. Manufact. 1985, 5, 31–34.

    OpenUrl
31. 31.↵
    1. Lydersen B. K.

    1. Lubiniecki A. S.

    Safety Considerations for Cell Culture–Derived Biologicals. In Large Scale Cell Culture; Lydersen B. K., Ed.; Carl Hanser: Munich, 1987; 231–247.
32. 32.↵
    1. Spier R. E.,
    2. Griffiths J. B.,
    3. Stephenne J.,
    4. Crooy P. J.

    1. Wiebe M. E.,
    2. Becker F.,
    3. Lazar R.,
    4. May L.,
    5. Casto B.,
    6. Semense C.,
    7. Fautz C.,
    8. Garnick R.,
    9. Miller C.,
    10. Massover G.,
    11. Bergmann D.,
    12. Lubiniecki A. S.

    A Multifaceted Approach To Assure That Recombinant tPA Is Free of Adventitious Virus. In Advances in Animal Cell Biology and Technology for Bioprocesses; Spier R. E., Griffiths J. B., Stephenne J., Crooy P. J., Eds.; Butterworths: London, 1989; pp 68–72.
33. 33.↵
    1. Mortimer P. P.,
    2. Luban N. L. C.,
    3. Kelleher J. F.,
    4. Cohen B. J.

    Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983, 2 (8348), 482–484.

    OpenUrlPubMedWeb of Science
34. 34.↵
    1. Mannucci P. M.

    Outbreak of hepatitis A among Italian patients with hemophilia. Lancet 1992, 339 (8796), 819.

    OpenUrlPubMed
35. 35.↵
    1. Garnick R. L.

    Experience with viral contaminaton in cell culture. Dev. Biol. Stand. 1996, 88, 49–56.

    OpenUrlPubMed
36. 36.↵
    Letters to biological manufacturers, FDA, May 3, 1991 and December 17, 1993.
37. 37.↵
    1. Spier R. E.,
    2. Griffiths J. B.,
    3. Stephenne J.,
    4. Crooy P. J.

    1. Lubiniecki A.,
    2. Arathoon R.,
    3. Polastri G.,
    4. Thomas J.,
    5. Wiebe M.,
    6. Garnick R.,
    7. Jones A.,
    8. van Reis R.,
    9. Builder S.

    Selected Strategies for Manufacture and Control of Recombinant Tissue Plasminogen Activator Prepared from Cell Cultures. In Advances in Animal Cell Biology and Technology for Bioprocesses; Spier R. E., Griffiths J. B., Stephenne J., Crooy P. J., Eds.; Butterworths: London, 1989; pp 442–451.
38. 38.↵
    1. Rabenau H.,
    2. Ohlinger V.,
    3. Anderson J.,
    4. Selb B.,
    5. Cinatl J.,
    6. Wolf W.,
    7. Frost J.,
    8. Mellor P.,
    9. Doerr H. W.

    Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 1993, 21 (3), 207–214.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Nims R. W.,
    2. Dusing S. K.,
    3. Hsieh W. T.,
    4. Lovatt A.,
    5. Reid G. G.,
    6. Onions D.,
    7. Milne E. W.

    Detection of Cache Valley virus in biologics manufactured in CHO cells. Biopharm. Intl. 2008, 21 (10), 89–94.

    OpenUrl
40. 40.↵
    1. Oehmig A.,
    2. Buttner M.,
    3. Weiland F.,
    4. Werz W.,
    5. Bergmann K.,
    6. Pfaff E.

    Identification of a calicivirus isolate of unknown origin. J. Gen. Virol. 2003, 84, 2837–2844.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Potts B. J.

    1. Hughes P. F.

    FDA perspective on mycoplasma contaminations in manufacturing dues to use of peptones. In Proceedings from the PDA Workshop on Mycoplasma Contamination by Plant Peptones; Potts B. J., Ed.; PDA: Rockville, MD, 2007; pp 73–92.
42. 42.↵
    1. Victoria G. J.,
    2. Wang C.,
    3. Jones M. S.,
    4. Jaing C.,
    5. McLoughlin K.,
    6. Gardner S.,
    7. Delwart E. L.

    Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033–6040.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    1. Kiss R.

    Practicing safe cell culture: applied process designs for minimizing virus contamination risk. PDA J. Pharm. Sci. Technol. 2011, 65 (6).
44. 44.↵
    1. Kiss R.,
    2. Drews R.

    1. Mercaldi M.

    Examining the effect of UV-C Irradiation on the biochemical properties of an IgG. In Kiss R., Drews R. Breakout Session A Summary. 2010 PDA-FDA meeting. DOI 10.5731/pdajpst.2011.00850.